Why a trial?, page-27

First 27 Last

Share
Profile

Follow
nippy

11,296 Posts.

716

10/08/23

00:49

Post #: 69258131
Share

Originally posted by Southoz: ↑

Simple rule of thumb is the more innocuous the contents of a CRL the happier companies will be to share the details.

Here we have two words – “more data”.

So the working assumption is that the FDA were completely unconvinced by the resubmission and have not budged one inch from their “at least one additional randomised controlled trial” position.

There is a slight possibility this might not be true.

In the first CRL MSB went straight to appeal; this had the effect of finalising the CRL.

In CRL2 MSB are heading to a Type A meeting. And so they can argue the process is still in progress; a incomplete negotiation. So with backwards and forwards still to come what is in the CRL today may not be there tomorrow.

Bear in mind that a CRL itself is a summary. A few pages summarising what will be hundreds / thousands lines of emails / discussions etc within the FDA. And so MSB might not have a good understanding around the FDA thinking behind some issues or how strongly their positions are held.

But realistically I don’t think anything now can change the path that gvhd is on. Which is heading to Gods waiting room. An academic network will be tasked with doing some design work and identifying opportunities for funding. In a couple of years only the old timers here will remember anything about it.

For now there is far more pressing issue of funding. If people recall a week or so ago I did a simple back of envelope risk reward calculation to get a handle on the market odds for probability of approval. I used an estimated downside share price of 80c in the case of rejection. Given a share price of around 110c my prognostication was the rejection would be a anti climax because the market was already pricing in failure.

This will make the top 5 of my silliest HC predictions.

I was completely oblivious to the financial consequences from the CRL. This was because finance is not my area of interest, I have no skills in it and consequently I never bother about it. Big mistake because the here the two – the clinical and finance were interlinked.

So that is one big lesson I have learned. Don’t forget that a biotech with complex opaque financial arrangements is a house of cards that may not be very resilient to a few puffs of wind from the FDA.

But from this perhaps flows the only glimmer of positivity I can see for MSB. We can debate SI’s skillset but no-one doubts his fund raising abilities. So SI might be the man for moment to put out this dumpster fire in a train wreck; which admittedly is of his own making.

Expand

Almost certainly have back pain partners lined up just waiting for the go switch to come on. The only discussion point is what form that takes and or pricing or % of future earnings if they go that way.

SI not even looking at that for the time being, however.

MSB Price at posting: 35.0¢ Sentiment: Buy Disclosure: Held
3 Upvote

0 Great analysis

Reply

Top Stories

CC9

Chariot locks in high-potential drill target at Black Mountain, one of the USA's largest lithium landholdings

INA

Ingenia shares jump 7% on strong revenue and earnings figures

Banking on ANZ in this week's Hot Stock tips

USL

'Joaquin Silver District' acquisition to become a key asset for Unico

UNT

UNITH hard launching AI 'digital human' platform too 600+ companies as AI thematic survives sell-off

There are more pages in this discussion • 81 more messages in this thread...

First 27 Last

Add MSB (ASX) to my watchlist

(20min delay)
Last 95.0¢		Change -0.045(4.52%)		Mkt cap ! $1.084B

Open	High	Low	Value	Volume
$1.00	$1.01	94.5¢	$2.669M	2.769M

Buyers (Bids)

No.	Vol.	Price($)
1	2053	95.0¢

Sellers (Offers)

Price($)	Vol.	No.
95.5¢	13191	2

View Market Depth

No.	Vol.	Price($)
1	2053	0.950
5	69192	0.945
16	152239	0.940
10	194253	0.935
9	112676	0.930

Price($)	Vol.	No.
0.955	13191	2
0.960	60726	4
0.965	33726	1
0.970	53885	3
0.975	54219	6

Last trade - 16.10pm 20/08/2024 (20 minute delay)

MSB (ASX) Chart

Why a trial?, page-27

Chariot locks in high-potential drill target at Black Mountain, one of the USA's largest lithium landholdings

Ingenia shares jump 7% on strong revenue and earnings figures

Banking on ANZ in this week's Hot Stock tips

'Joaquin Silver District' acquisition to become a key asset for Unico

UNITH hard launching AI 'digital human' platform too 600+ companies as AI thematic survives sell-off

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Why a trial?, page-27

Top Stories

Chariot locks in high-potential drill target at Black Mountain, one of the USA's largest lithium landholdings

Ingenia shares jump 7% on strong revenue and earnings figures

Banking on ANZ in this week's Hot Stock tips

'Joaquin Silver District' acquisition to become a key asset for Unico

UNITH hard launching AI 'digital human' platform too 600+ companies as AI thematic survives sell-off

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News